COMMUNIQUÉS West-GlobeNewswire

Oculis Publishes Results of 2025 Annual General Meeting
05/06/2025
ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at [...]
MEME Coins Inc. Closes Acquisition of 1 Billion Dogecoin Cash (DOG) Tokens from Tipestry Inc.
05/06/2025
Transaction finalized with issuance of 125,000 preferred MEME Coin shares; token transfer confirmed on BSCScan Mesquite, June 05, 2025 (GLOBE NEWSWIRE) -- June 5, 2025 – Mesquite, NV — Dogecoin Cash Inc. (OTC: CBDS) [...]
Merus N.V. annonce une offre publique de souscription d’actions ordinaires
05/06/2025
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 05 juin 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous » et « notre »), une société spécialisée dans l’oncologie qui développe des [...]
Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 s release
05/06/2025
Final results expected in H2 2025 Lyon, France – June 5, 2025 – Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, today announced [...]
AstriVax Therapeutics Initiates Clinical Development of AVX70371, a Hepatitis B immunotherapy using Launch-iT technology
05/06/2025
Third asset to advance into clinical trials, validating broad potential of Launch-iT platform All subjects treated with first dose of AVX70371 Launch-iT, as part of multiple dosing schedule Potential first-in-class [...]
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference
05/06/2025
Geneva, Switzerland, June 5, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological [...]
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea
05/06/2025
Allschwil, Switzerland, June 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections [...]
[Valneva SE] Déclaration d’actions et de droits de vote - mai 2025
05/06/2025
VALNEVA Déclaration d’actions et de droits de vote 31 mai 2025 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : 6 rue [...]
[Valneva SE] Declaration of shares and voting rights - May 2025
05/06/2025
VALNEVA Declaration of shares and voting rights May 31, 2025 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 [...]
Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan
05/06/2025
Ro5 Inc. acquisition enhances artificial intelligence/machine learning drug discovery capabilities Strategic addition strengthens Juvenescence’s AI-enabled therapeutics pipeline and supports partnership with M42 ( [...]
EssilorLuxottica va acquérir les chaines de magasins A-Look, Seen et OWL en Malaisie
05/06/2025
EssilorLuxottica va acquérir les chaines de magasins A-Look, Seen et OWL en Malaisie Avec cette opération, le Groupe vise à améliorer la santé visuelle dans le pays Paris, France (5 Juin 2025) – EssilorLuxottica a [...]
EssilorLuxottica signs an agreement to acquire A-Look, Seen and OWL retail stores in Malaysia
05/06/2025
EssilorLuxottica signs an agreement to acquire A-Look, Seen and OWL retail stores in Malaysia With this transaction, the Group aims at further elevating the standards of vision care in the country Paris, France (5 June [...]
Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering
05/06/2025
NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for [...]
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
05/06/2025
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA [...]
NeuroPace Secures Up to $75 Million in Debt Financing
04/06/2025
MOUNTAIN VIEW, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company has [...]
SI-BONE to Present at Truist Securities MedTech Conference on June 17, 2025
04/06/2025
SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 mai 2025
04/06/2025
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 mai 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025
04/06/2025
Information regarding the total number of voting rights and total number of shares of the Company as of May 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/06/2025
BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]

Pages